VitaNova Life Sciences Corp (VNOV)
VNOV is quoted over the counter, not listed on an exchange. VitaNova Life Sciences Corp files reports with the SEC; the numbers below come from SEC filings and from daily closes, each with its source.
Closes: Yahoo Finance daily closes, last bar 2026-11-13.
Profile
| Field | Value |
|---|---|
| Ticker | VNOV, quoted over the counter |
| SEC CIK | 0001699709 |
| OTC Markets tier | OTCID (price source, 2026-11-13) |
| SEC industry code | Wholesale-Apparel, Piece Goods & Notions |
| Business address | New York, NY |
| Incorporated in | NV |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-09-14 |
| Cash and burn | $1.6M cash; operating cash flow $139K a quarter. | Report 2026-07-31 |
| Shares outstanding | 8,337,454 (2026-09-14); 25,012,270 a year earlier; 5,871,250 three years earlier. 1y figure adjusted for split (1-for-3 overall); 3y figure adjusted for split (1-for-3 overall). | Cover page 2026-09-14 |
| Reverse splits, 3 years | 1; latest 1-for-3 on 2026-01-27 | Source 2026-01-27 |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Simon & Edward, LLP, Rowland Heights, California, United States | PCAOB Form AP 2026-08-06 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q1 2027 2026-07-31 | $322K | -$123K | $7K | $1.6M | No debt tags | $3.2M | 10-Q 2026-09-14 |
| Q4 2026 2026-04-30 | $1.8M | $18K | $428K | $1.6M | No debt tags | $3.0M | 10-K 2026-07-29 |
| Q3 2026 2026-01-31 | $710K | -$44K | -$90K | $1.2M | No debt tags | $3.2M | 10-Q 2026-03-16 |
| Q2 2026 2025-10-31 | $427K | $36K | $213K | $1.3M | No debt tags | $2.8M | 10-Q 2025-12-15 |
| Q1 2026 2025-07-31 | $104K | -$46K | $264K | $1.0M | No debt tags | $2.7M | 10-Q 2026-09-14 |
| Q4 2025 2025-04-30 | $2.0M | $800K | $479K | $783K | No debt tags | $2.7M | 10-K 2026-07-29 |
| Q3 2025 2025-01-31 | $308K | $73K | $209K | $405K | No debt tags | $1.3M | 10-Q 2026-03-16 |
| Q2 2025 2024-10-31 | $292K | $33K | $9K | $223K | No debt tags | $971K | 10-Q 2025-12-15 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | POS AM | 2023-05-24 |
| Latest annual report | 10-K | 2026-07-29 |
| Latest quarterly / interim | 10-Q | 2026-09-14 |
| Latest current report | 8-K | 2026-03-18 |
Source: SEC EDGAR submissions feed, 97 recent filings. All filings on EDGAR.
The full dossier has every filing, quarterly and annual financials, the health record and a price chart.
Open the full dossier